2Xiong F, Sun M, Zhang X, et al. Molecular epidemiological survey of hemoglobinopathies in the Guangxi Zhuang autonomous region of southern China[J]. Clin Genet, 2010, 78(2) : 139-148.
3Zhang J, Zhu BS, He Jing, et al. The spectrum of α- and β-thalas- semia mutations in Yunnan province of southwestern China [ J ]. He- moglobin,2012,36 (5) :464-473.
4Taher AT,Cappellini MD,Musallam KM.Recent advances and treatment challenges in patients with non-transfusion-dependent thalassemia[J].Blood Rev,2012,26(Suppl 1):S1-S2.
5Lal A,Porter J,Sweeters N,et al.Combined chelation therapy with deferasirox and deferoxamine in thalassemia[J].Blood Cells Mol Dis,2013,50(2):99-104.
6Cassinerio E,Orofino N,Roghi A,et al.Combination of deferasirox and deferoxamine in clinical practice:an alternative scheme of chelation in thalassemia major patients[J].Blood Cells Mol Dis,2014,53(3):164-167.
7Hamidieh AA,Saber T,Fayyazi S,et al.Impact ofβ-globin mutations on outcome of matched related donor hematopoietic stem cell transplantation for patients withβ-Thalassemia Major[J].Biol Blood Marrow Transplant,2014,(20):1772-1776.
8Galambrun C,PondarréC,Bertrand Y,et al.French multicenter22-year experience in stem cell Transplantation for beta-thalassemia major:lessons and future directions[J].Biol Blood Marrow Transplant,2013,19(1):62-68.
9Cavazzana-Calvo M,Payen E,Negre O,et al.Transfusion independ-ence and HMGA2 activation after gene therapy of human beta-thalas-saemia[J].Nature,2010,467(7313):318-322.
10Ye L,Chang JC,Lin C,et al.Induced pluripotent stem cells offer newapproach to therapy in thalassemia and sickle cell anemia and option inprenatal diagnosis in genetic diseases[J].Proc Natl Acad Sci USA,2009,106(24):9826-9830.
